difference of semaglutide and tirzepatide vs GLP-1 Medications for Weight Loss:

Sodium-Glucose Co-Transporter-2 Inhibitors Sodium-glucose co-transporter-2 (SGLT-2) inhibitors are currently licensed for the treatment of T2D, though there is a growing body of evidence to support their use in cardiovascular [56] and renal disease [57]

Osthole targeted AMPK, inhibited the secretion of inflammatory factors from FLS, restored mitochondrial homeostasis, and promoted the apoptosis in FLS by inhibiting the activation of NLRP3 (117)

Wegovy frequently causes nausea, vomiting, diarrhoea, constipation, and abdominal discomfort, especially during dose escalation

"FDA Approves Oral Semaglutide for Chronic Weight Management." fda.gov Novo Nordisk